Mercachem logo voor websites

Update COVID-19:

The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.

The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.


We firmly believe in the underlying chemical principles of the ELF project. Apart from producing 40,000 compounds, we have been extensively involved in the organisation of this collaboration.

WP10: Review & Selection

Jorg Benningshof (Director of Parallel Chemistry) is part of the library selection committee. The committee reviews library proposals according to novelty, innovation, and complementarity to existing scaffolds. To date, close to 900 scaffolds have been evaluated.

A recent paper in Drug Discovery Today reported the efforts of the library selection committee and the prospects of the ELF Project.

WP11: Experimental Validation

Luc Van Hijfte (Senior Vice President of Medicinal Chemistry) and Jorg Benningshof are supervising this work package. As such, they are responsible for the validation of syntheses and scaling up of scaffolds. Validation also includes the detailed scope of chemistry possible at a minimum of two variation points on a scaffold.

As of today, approximately 225 scaffolds have been chemically validated and subjected to library production.

WP12: Library generation

Mercachem is one of the small- and medium-sized enterprises (SMEs) responsible for the production of libraries based on validated scaffolds. The aim is to produce 8000 compounds annually, based on 16 new scaffolds.